Replies to post #8970 on Avid Bioservices Inc (CDMO)

[jazzbeerman]

re: bavi + ribavirin-

six months ago from Q&A of the 3-13-06 CC:

Joe P., Canaccord-Adams: Hep repeat-dose: design?, #patients? b. HepC combo: only combo with approved drugs or experimental too?

SK: “We’ll be looking at repeat doses of Tarvacin based on the pharmacokinetic data we obtained in the ph1 trial, given probably at several diff. dose levels. Combo-therapy trials are trickier to do with experimental drugs, so we’re going to be combining in Ribavirin and/or pegylated interferon – those are the 2 frontline therapies right now for HepC. We have ongoing pre-clinical studies evaluating combo’s of Tarvacin with each of the potential drugs we can combine with. We have some positive data already, looking at Tarvacin+Ribavirin, so that’s a good possibility.”



--------



j